Aries Pharmaceuticals, Inc. Shares Positive Results for Clinical Study of Eleview™ at Digestive Disease Week Annual Meeting
Effectiveness and Safety Positively Demonstrated Against Standard of Care; Convenient “Twist and Go” Packaging Unveiled
Rifamycin SV MMX
A non-absorbable antibiotic for the treatment of bacterial infections of the colon.
novel application of methylene blue to stain the mucosa to discover pre-cancerous lesions and polyps
The Director of Marketing will be a key member of the Marketing department, and overall company leadership team, charged to shape commercialization strategy for Aries’ planned 2018 US launch of our first pharmaceutical product within the colorectal cancer market (proprietary Methylene Blue MMX® for detection of pre-cancerous and cancerous lesions and polyps throughout the colon).
Director, Value & Access
The Director of Value & Access will help lead Aries’ creation and implementation of best-in-class Value & Access capabilities leading to access and profit optimization of Aries’ pharmaceutical and device product portfolio.
Medical Science Liaison – Southern California
The Medical Science Liaison (MSL) is a field-based member of Medical/Scientific Affairs. The MSLs will interact often with Aries Medical Affairs, the clinical team, and Scientific Affairs in support of current and future products.